NYSE
CRY

CryoLife, Inc

Prices are adjusted according to historical splits.

CryoLife, Inc Stock Price

Vitals

Today's Low:
$
Today's High:
$
Open Price:
$
52W Low:
$12.63
52W High:
$31.39
Prev. Close:
$
Volume:

Company Statistics

Market Cap.:
$0.692 billion
Book Value:
7.845
Revenue TTM:
$0.258 billion
Operating Margin TTM:
2.03%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
-4.33%
Return on Assets TTM:
0.51%
Return on Equity TTM:
-3.86%

Company Profile

CryoLife, Inc had its IPO on 1993-02-12 under the ticker symbol CRY.

The company operates in the sector and industry. CryoLife, Inc has a staff strength of 1,200 employees.

Stock update

Shares of CryoLife, Inc opened at $0 at the start of the last trading session i.e. .

The stocks traded within a range of $0 - $0, and closed at $0.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of CryoLife, Inc have increased by 0%.

CryoLife, Inc's Key Ratios

CryoLife, Inc has a market cap of $0.692 billion, indicating a price to book ratio of 2.3655 and a price to sales ratio of 2.7095.

In the last 12-months CryoLife, Inc’s revenue was $0.258 billion with a gross profit of $0.000 billion and an EBITDA of $0.024 billion. The EBITDA ratio measures CryoLife, Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, CryoLife, Inc’s operating margin was 2.03% while its return on assets stood at 0.51% with a return of equity of -3.86%.

In Q2, CryoLife, Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 24.4%.

CryoLife, Inc’s PE and PEG Ratio

Forward PE
142.8571
Trailing PE
504
PEG
71.2692

Its diluted EPS in the last 12-months stands at $-0.297 per share while it has a forward price to earnings multiple of 142.8571 and a PEG multiple of 71.2692. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CryoLife, Inc’s profitability.

CryoLife, Inc stock is trading at a EV to sales ratio of 3.4421 and a EV to EBITDA ratio of 42.0454. Its price to sales ratio in the trailing 12-months stood at 2.7095.

CryoLife, Inc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

CryoLife, Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

CryoLife, Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

CryoLife, Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, CryoLife, Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, CryoLife, Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$0
52-Week High
$31.39
52-Week Low
$12.63
Analyst Target Price
$26.5

CryoLife, Inc stock is currently trading at $0 per share. It touched a 52-week high of $31.39 and a 52-week low of $31.39. Analysts tracking the stock have a 12-month average target price of $26.5.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 17.56 indicating a short percent outstanding of 10%.

Around 387.7% of the company’s stock are held by insiders while 7839.7% are held by institutions.

Frequently Asked Questions About CryoLife, Inc

The stock symbol (also called stock or share ticker) of CryoLife, Inc is CRY

The IPO of CryoLife, Inc took place on 1993-02-12

Similar Industry Stocks ()

Last Price
Chg
Chg%
$12.97
-0.23
-1.71%
$140.67
-4.48
-3.09%
$178.62
-1.24
-0.69%
$0.92
0.06
+7.49%
$10.55
-0.02
-0.19%
$36.07
0.57
+1.61%
Urban One (UONE)
$5.75
-0.32
-5.27%
$20.89
-2.28
-9.84%
$41.93
-0.83
-1.94%
Fortis Inc (FTS)
$38.74
0.03
+0.08%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products, a range of stent graft systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G, a stent graft system for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers vascular preservation services; synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products, such as YAG laser consoles, related service and maintenance, and single-use, fiber-optic handpieces; and CryoVein femoral vein and CryoArtery femoral artery vascular preservation services for vascular access. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Address

1655 Roberts Boulevard N.W., Kennesaw, GA, United States, 30144